FDA Proposes Selection Process for Patient Reps

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

ROCKVILLE, Md--The FDA has proposed a formal process for selecting patient representatives to serve on its cancer-related advisory boards--the Onco-logic Drugs Advisory Committee, the Biological Response Modifiers Advisory Committee, and the Medical Imaging Drugs Advisory Committee.

ROCKVILLE, Md--The FDA has proposed a formal process for selecting patientrepresentatives to serve on its cancer-related advisory boards--the Onco-logicDrugs Advisory Committee, the Biological Response Modifiers Advisory Committee,and the Medical Imaging Drugs Advisory Committee.

Patient representatives are called for in President Clinton's FDA Initiativeon Reinventing the Regulation of Cancer Drugs, released on March 29, 1996.

In the Jan. 15, 1997, Federal Register, the FDA outlined its proposedsystem to recruit, assess, select, and train the patient representatives,who will have full voting authority when the committees make recommendationsto the agency.

"The primary role of the patient representative would be to provideto the advisory committee the perspective of the patient with the diseasefor which the therapeutic agent is being considered," the FDA said.It set seven qualifications that potential patient representatives mustmeet:

  • Personal experience with a cancer.
  • Experience as a patient advocate.
  • Formal affiliation with a patient advocacy organization.
  • Ability to articulate the perspective of the patient.
  • Ability to identify issues through communications with patient constituencies.
  • Access to ways to disseminate information from an advisory committeemeeting to the affected community.
  • Experience in the technical issues before the committee.

Nominations can be made by individuals, including self-nominations,and by patient advocacy groups and organizations.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.